Zynex, Inc.

NasdaqGS ZYXI

Zynex, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD -30.41 M

Zynex, Inc. Net Cash Used Provided By Financing Activities is USD -30.41 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -331.52% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • Zynex, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 13.14 M, a 210.90% change year over year.
  • Zynex, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -11.85 M, a -304.27% change year over year.
  • Zynex, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -2.93 M, a -111.50% change year over year.
  • Zynex, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 25.47 M, a 1,048.60% change year over year.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
Loading...
SV Wall Street
NasdaqGS: ZYXI

Zynex, Inc.

CEO Mr. Thomas Sandgaard
IPO Date Feb. 25, 2004
Location United States
Headquarters 9655 Maroon Circle
Employees 1,100
Sector Healthcare
Industries
Description

Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

Similar companies

HSIC

Henry Schein, Inc.

USD 80.00

-0.04%

MCK

McKesson Corporation

USD 594.75

-1.63%

EDAP

EDAP TMS S.A.

USD 2.44

6.09%

CAH

Cardinal Health, Inc.

USD 123.66

-3.59%

PDCO

Patterson Companies, Inc.

USD 30.95

-0.13%

OMI

Owens & Minor, Inc.

USD 14.24

-2.47%

StockViz Staff

February 3, 2025

Any question? Send us an email